FYLD | $41,000,000 | (Feb 18, 2026)
The Compression Company | $3,400,000 | (Feb 18, 2026)
Helia Care, Inc. | $3,000,000 | (Feb 18, 2026)
Certified by Founder
Lodge
Exeliom Biosciences
start up
France
- Dijon, Bourgogne-Franche-Comté
- 21/07/2023
- Series A
- $8,898,320
At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
- Industry Pharmaceutical Manufacturing
- Website https://www.exeliombio.com/
- LinkedIn https://www.linkedin.com/company/nextbiotix/
Related People
Benjamin HadidaFounder
France -
Paris, Île-de-France
Biotech company builder and new therapeutic class explorer
Dataro | $14,280,000 | (Feb 18, 2026)
Daffodil Health Corp | $16,300,000 | (Feb 18, 2026)
Sphinx(US) | $7,100,000 | (Feb 18, 2026)
Autosana (YC S25) | $3,200,000 | (Feb 18, 2026)
Tangible | $4,300,000 | (Feb 18, 2026)
Certivo | $4,000,000 | (Feb 18, 2026)
GelMEDIX | $13,000,000 | (Feb 18, 2026)
QuadSci.ai | $8,000,000 | (Feb 18, 2026)
Breaker | $6,000,000 | (Feb 18, 2026)
Bland Company | $2,670,000 | (Feb 18, 2026)